MBRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

-6.583

-90.76%

-11.250

-34.78%

Estimates Revision

The market is revising No Change the revenue expectations for Moleculin Biotech, Inc. (MBRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -66.41%.

EPS Estimates for FY2025

Revise Upward

+26.75%

In Past 3 Month

Stock Price

Go Down

-66.41%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast MBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 6.67 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

6.67

High

12.00

Current: 0.000

Low

4.00

Averages

6.67

High

12.00

Roth Capital

Jonathan Aschoff

Buy

downgrade

$300 -> $31

2025-12-15

Reason

Roth Capital

Jonathan Aschoff

Price Target

$300 -> $31

2025-12-15

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Moleculin Biotech to $31 from $300 and keeps a Buy rating on the shares following the 1-for-25 reverse stock split. The firm says enrollment in the Phase2b/3 MIRACLE trial is progressing as anticipated, with initial results expected in Q1 of 2026.

H.C. Wainwright

Buy

upgrade

$4 -> $22

2025-12-11

Reason

H.C. Wainwright

Price Target

$4 -> $22

2025-12-11

upgrade

Buy

Reason

H.C. Wainwright adjusted the firm's price target on Moleculin Biotech to $22 from $4 and keeps a Buy rating on the shares following the 1-for-25 reverse split.

Roth Capital

Jonathan Aschoff

Buy

downgrade

$20 -> $13

2025-06-27

Reason

Roth Capital

Jonathan Aschoff

Price Target

$20 -> $13

2025-06-27

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Moleculin Biotech to $13 from $20 and keeps a Buy rating on the shares following the recent capital raise. The firm cites financial model adjustments for the target cut. Roth believes Moleculin's warrant exercise should be able to fund operations to the end of 2025, given the MIRACLE trial unblinded initial interim data announcement from 45 patients that it expects in the second half of 2025.

H.C. Wainwright

initiated

2025-06-09

Reason

H.C. Wainwright

Price Target

2025-06-09

initiated

Reason

H.C. Wainwright assumed coverage of Moleculin Biotech with a Buy rating and $4 price target. Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

2025-03-25

Reason

Maxim Group

Jason McCarthy

Price Target

2025-03-25

Upgrades

Hold

Strong Buy

Reason

Maxim analyst Jason McCarthy upgraded Moleculin Biotech to Buy from Hold with a $4 price target.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-03-25

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-25

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Moleculin Biotech Inc (MBRX.O) is -0.23, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess Moleculin Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.49

Current PE

-0.23

Overvalued PE

0.13

Undervalued PE

-3.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.03

Current EV/EBITDA

-0.18

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-0.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MBRX News & Events

Events Timeline

No data

News

2.0

2025-12-17NASDAQ.COM

Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors

9.0

2025-12-17NASDAQ.COM

Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study

2.0

2025-12-09Globenewswire

Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial

People Also Watch

Frequently Asked Questions

What is Moleculin Biotech Inc (MBRX) stock price today?

The current price of MBRX is 3.98 USD — it has decreased -3.16 % in the last trading day.

What is Moleculin Biotech Inc (MBRX)'s business?

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

What is the price predicton of MBRX Stock?

What is Moleculin Biotech Inc (MBRX)'s revenue for the last quarter?

Moleculin Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Moleculin Biotech Inc (MBRX)'s earnings per share (EPS) for the last quarter?

Moleculin Biotech Inc. EPS for the last quarter amounts to -17.02 USD, decreased -76.13 % YoY.

What changes have occurred in the market's expectations for Moleculin Biotech Inc (MBRX)'s fundamentals?

How many employees does Moleculin Biotech Inc (MBRX). have?

Moleculin Biotech Inc (MBRX) has 17 emplpoyees as of January 10 2026.

What is Moleculin Biotech Inc (MBRX) market cap?

Today MBRX has the market capitalization of 12.26M USD.